The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also available. Competition is also intensifying among antipsychotic long-acting injectables (LAIs) as new therapies launch, offering largely incremental advantages over treatment mainstays. Indeed, late-phase emerging therapies—including new oral atypical antipsychotics (Alkermes’s ALKS 3831, Acadia Pharmaceuticals’ pimavanserin), new LAIs (e.g., Janssen’s paliperidone six-month depot, Teva’s TV-46000), and others (Sunovion / Sumitomo Dainippon Pharma’s SEP-363856, BioXcel’s BXCL501)—must be clearly differentiated from established therapies to gain a foothold in this market. The potential of early- to mid-phase therapies to treat the negative symptoms and cognitive impairment associated with schizophrenia (CIAS)—symptom domains on which drug developers are increasingly focusing—remains to be seen; few agents have promising results in mid-phase clinical studies (e.g., Boehringer Ingelheim’s BI 425809 in CIAS).
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What factors drive and constrain the use of LAIs of atypical antipsychotics? How is competition heating up in this segment?
- What are the biggest areas of unmet need? Which late-phase therapies have potential to fulfill these needs?
- What would key late-phase therapies need to demonstrate in order to compete effectively in this crowded market? How will these agents be placed in the schizophrenia treatment algorithm?
Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Geographies: United States, EU5, Japan.
Primary research: 29 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms and negative symptoms; drug-treated prevalence of schizophrenia by country.
Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2029, segmented by brands / generics.
Emerging therapies: Phase III / PR: 10 drugs. Coverage of select Phase II and Phase I products.